35 results on '"Carfagno, T"'
Search Results
2. Assessment of response to chemoradiation therapy in rectal cancer using MR volumetry based on diffusion-weighted data sets: a preliminary report
- Author
-
Carbone, S. F., Pirtoli, L., Ricci, V., Venezia, D., Carfagno, T., Lazzi, S., Mourmouras, V., Lorenzi, B., and Volterrani, L.
- Published
- 2012
- Full Text
- View/download PDF
3. 305. Can magnetic-resonance-imaging volumetric texture analysis predict treatment outcome in rectal cancer patients undergoing neoadjuvant chemo-radiation?
- Author
-
Biondi, M., primary, Vanzi, E., additional, De Otto, G., additional, Belmonte, G., additional, Nardone, V., additional, Cirigliano, A., additional, Grassi, A., additional, Carbone, S.F., additional, Tini, P., additional, Sebaste, L., additional, Carfagno, T., additional, Battaglia, G., additional, Rubino, G., additional, Pastina, P., additional, Correale, P., additional, Nioche, C., additional, Pirtoli, L., additional, and Banci Buonamici, F., additional
- Published
- 2018
- Full Text
- View/download PDF
4. 304. Role of texture analysis (TA) as prognostic factor in patients with glioblastoma diagnosis subject to radio-chemotherapic treatment concerning post-operating tomozolomide
- Author
-
Biondi, M., primary, Vanzi, E., additional, De Otto, G., additional, Belmonte, G., additional, Nardone, V., additional, Tini, P., additional, Sebaste, L., additional, Carfagno, T., additional, Battaglia, G., additional, Rubino, G., additional, Pastina, P., additional, Pirtoli, L., additional, and Banci Buonamici, F., additional
- Published
- 2018
- Full Text
- View/download PDF
5. 107. Magnetic-resonance-imaging texture analysis predicts early progression in rectal cancer patients undergoing neoadjuvant chemo-radiation
- Author
-
Biondi, M., primary, Vanzi, E., additional, De Otto, G., additional, Belmonte, G., additional, Nardone, V., additional, Cirigliano, A., additional, Grassi, A., additional, Carbone, S.F., additional, Tini, P., additional, Sebaste, L., additional, Carfagno, T., additional, Battaglia, G., additional, Rubino, G., additional, Pastina, P., additional, Correale, P., additional, Nioche, C., additional, Pirtoli, L., additional, and Buonamici, F. Banci, additional
- Published
- 2018
- Full Text
- View/download PDF
6. P2.07-046 Nivolumab Exerts Remarkable Antitumor Activity in NSCLC After an Immune-Modulating Biochemotherapy Regimen
- Author
-
Pastina, P., primary, Nardone, V., additional, Botta, C., additional, Croci, S., additional, Davì, D., additional, Tini, P., additional, Battaglia, G., additional, Sebaste, L., additional, Carfagno, T., additional, Carbone, S.F., additional, Ricci, V., additional, Giannicola, R., additional, Tagliaferri, P., additional, Pirtoli, L., additional, and Correale, P., additional
- Published
- 2017
- Full Text
- View/download PDF
7. Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma
- Author
-
Cencini, E., primary, Puccini, B., additional, Rigacci, L., additional, Fabbri, A., additional, Kovalchuk, S., additional, Benelli, G., additional, Mannelli, L., additional, Carfagno, T., additional, Simontacchi, G., additional, Bocchia, M., additional, and Bosi, A., additional
- Published
- 2017
- Full Text
- View/download PDF
8. Tumor infiltration by T lymphocytes correlates with the outcome of prostate cancer patients treated with salvage radiotherapy
- Author
-
Nardone, V., primary, Botta, C., additional, Ambrosio, M.R., additional, Carfagno, T., additional, Tini, P., additional, Del Vecchio, M.T., additional, Caraglia, M., additional, Tagliaferri, P., additional, Pirtoli, L., additional, and Correale, P., additional
- Published
- 2016
- Full Text
- View/download PDF
9. Prognostic role of texture analysis in lung cancer treated with stereotactic ablative radiotherapy (SABR)
- Author
-
Nardone, V., primary, Tini, P., additional, Mazzoni, L.N., additional, Penna, A.L.a., additional, Biondi, M., additional, Sebaste, L., additional, Carfagno, T., additional, Vanzi, E., additional, De Otto, G., additional, Battaglia, G., additional, Pastina, P., additional, Carbone, S.F., additional, Buonamici, F. Banci, additional, and Pirtoli, L., additional
- Published
- 2016
- Full Text
- View/download PDF
10. Analisi del rischio proattiva: l’esperienza della U.O. di Radioterapia dell’Azienda Ospedaliera Universitaria Senese
- Author
-
Carfagno, T., Russo, Carmela, Burrini, A., Erre, M. L., D'Ippolito, Edoardo, and Messina, Gabriele
- Published
- 2014
11. Inflammatory status and lymphocyte of infiltration of primary tumor predict survival of prostate cancer patients undergone prostate radical radiotherapy
- Author
-
Carfagno, T., primary, Semeraro, L., additional, Nardone, V., additional, Vischi, G., additional, Ferrara, P., additional, Ambrosio, M., additional, Barone, A., additional, Martino, E., additional, Pastina, P., additional, Pirtoli, L., additional, and Correale, P., additional
- Published
- 2015
- Full Text
- View/download PDF
12. Assessment of response to chemoradiation therapy in rectal cancer using MR volumetry based on diffusion-weighted data sets: a preliminary report [La volumetria con risonanza magnetica pesata in diffusione nella valutazione della risposta alla chemio-radioterapia nel tumore del retto: studio preliminare]
- Author
-
Carbone, S. F., Pirtoli, Luigi, Ricci, V., Venezia, D., Carfagno, T., Lazzi, Stefano, Mourmouras, V., Lorenzi, B., and Volterrani, Luca
- Published
- 2012
13. Adjuvant radiotherapy after radical prostatectomy: multinstitutional experience
- Author
-
Detti, B, Livi, L, Greto, D, Iermano, C, Bruni, A, Semere, G, Nosi, F, DE MAJO, R, Borghesi, S, Pirtoli, Luigi, Carfagno, T, Buonfrate, G, Gennari, P, Malangone, V, Stefanacci, M, Vezzani, E, Santini, R, and Biti, G. P.
- Published
- 2009
14. The Activity Based Costing (ABC) evaluation in radiotherapy: a comparison between 3D-CRT, IMRT and IGRT
- Author
-
Berti, V, Sebaste, L, Carfagno, T, Pepi, F, DEL TREDICI, S, Giani, A, and Pirtoli, Luigi
- Published
- 2007
15. 13P - Tumor infiltration by T lymphocytes correlates with the outcome of prostate cancer patients treated with salvage radiotherapy
- Author
-
Nardone, V., Botta, C., Ambrosio, M.R., Carfagno, T., Tini, P., Del Vecchio, M.T., Caraglia, M., Tagliaferri, P., Pirtoli, L., and Correale, P.
- Published
- 2016
- Full Text
- View/download PDF
16. 1185P - Prognostic role of texture analysis in lung cancer treated with stereotactic ablative radiotherapy (SABR)
- Author
-
Nardone, V., Tini, P., Mazzoni, L.N., Penna, A.L.a., Biondi, M., Sebaste, L., Carfagno, T., Vanzi, E., De Otto, G., Battaglia, G., Pastina, P., Carbone, S.F., Buonamici, F. Banci, and Pirtoli, L.
- Published
- 2016
- Full Text
- View/download PDF
17. [Restaging brain computerized tomography after treatment of non-operable lung neoplasms]
- Author
-
Pirtoli, Luigi, Tucci, E., Bellezza, A., Volterrani, Luca, Carfagno, T., Crastolla, A. M., Pepi, F., and Sebaste, L.
- Subjects
Adult ,Male ,Survival Rate ,Lung Neoplasms ,Brain Neoplasms ,Humans ,Female ,Middle Aged ,Tomography, X-Ray Computed ,Aged ,Follow-Up Studies ,Neoplasm Staging - Abstract
To assess the role of CT brain scans as a routine restaging procedure after primary, aggressive, drug or radiation therapy of unresectable lung cancer. If early, asymptomatic brain metastases are detected and treated, survival could be improved relative to the patients showing brain involvement in a later CT scan performed during the follow-up, at the onset of neurological symptoms.One hundred patients affected with lung cancer, unresectable on account of histology (small-cell carcinoma) or advanced stage (III, IV) were submitted to chemo- and/or radiotherapy, after a clinical staging including brain CT, which was negative in all patients. Brain CT was also repeated at the end of therapy (restaging), in the absence of any neurological symptom. Further scans were obtained during the subsequent follow-up only when clinical symptoms occurred, suggesting metastases to the brain. Survival values were analyzed in the patients whose brain involvement was detected during restaging, vs those showing symptomatic brain metastases during the follow-up.Only 4 patients had asymptomatic metastases, diagnosed with the restaging brain CT scan. Their survival rate was significantly lower than that of the 20 patients whose brain involvement was shown by a follow-up CT scan, performed after the onset of neurological symptoms. However, death was rarely a consequence of brain metastases: primary or other metastatic sites were involved in the terminal events, in the greatest majority of these cases.The sudden, asymptomatic brain involvement, detected at restaging CT scan after primary therapy for unresectable lung cancer, does not correlate with a better prognosis than symptomatic metastases, diagnosed later with a follow-up CT obtained performed for clinical suspicion. Therefore the use of restaging CT scan is not warranted, as a routine procedure, except for the clinical trials intended to define optimal treatment schedules.
- Published
- 1998
18. Putative Role of Circulating Human Papillomavirus DNA in the Development of Primary Squamous Cell Carcinoma of the Middle Rectum: A Case Report
- Author
-
Maria Raffaella Ambrosio, Remo Vernillo, Sabrina De Carolis, Antonietta Carducci, Lucia Mundo, Alessandro Ginori, Bruno Jim Rocca, Valerio Nardone, Alessandra Lucenti Fei, Tommaso Carfagno, Stefano Lazzi, Monica Cricca, Piero Tosi, Ambrosio M.R., Vernillo R., De Carolis S., Carducci A., Mundo L., Ginori A., Rocca B.J., Nardone V., Fei A.L., Carfagno T., Lazzi S., Cricca M., Tosi P., Ambrosio, M. R., Vernillo, R., De Carolis, S., Carducci, A., Mundo, L., Ginori, A., Rocca, B. J., Nardone, V., Fei, A. L., Carfagno, T., Lazzi, S., Cricca, M., and Tosi, P.
- Subjects
0301 basic medicine ,Cancer Research ,Stromal cell ,circulating HPV ,Case Report ,In situ hybridization ,exosomes ,Biology ,lcsh:RC254-282 ,Exosome ,middle rectum ,03 medical and health sciences ,0302 clinical medicine ,Cancer stem cell ,cancer ,Neoplastic transformation ,Cancer, Circulating HPV, Exosomes, Immune evasion, Middle rectum ,Induced pluripotent stem cell ,immune evasion ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,030104 developmental biology ,Oncology ,Cell culture ,030220 oncology & carcinogenesis ,Cancer research ,Stem cell - Abstract
Here we present the case of a patient affected by rectal squamous cell carcinoma in which we demonstrated the presence of Human Papillomavirus (HPV) by a variety of techniques. Collectively, the virus was detected not only in the tumor but also in some regional lymph nodes and in non-neoplastic mucosa of the upper tract of large bowel. By contrast, it was not identifiable in its common sites of entry, namely oral and ano-genital region. We also found HPV DNA in the plasma-derived exosome. Next, by in vitro studies, we confirmed the capability of HPV DNA-positive exosomes, isolated from the supernatant of a HPV DNA positive cell line (CaSki), to transfer its DNA to human colon cancer and normal cell lines. In the stroma nearby the tumor mass we were able to demonstrate the presence of virus DNA in the stromal compartment, supporting its potential to be transferred from epithelial cells to the stromal ones. Thus, this case report favors the notion that human papillomavirus DNA can be vehiculated by exosomes in the blood of neoplastic patients and that it can be transferred, at least in vitro, to normal and neoplastic cells. Furthermore, we showed the presence of viral DNA and RNA in pluripotent stem cells of non-tumor tissue, suggesting that after viral integration (as demonstrated by p16 and RNA in situ hybridization positivity), stem cells might have been activated into cancer stem cells inducing neoplastic transformation of normal tissue through the inactivation of p53, p21, and Rb. It is conceivable that the virus has elicited its oncogenic effect in this specific site and not elsewhere, despite its wide anatomical distribution in the patient, for a local condition of immune suppression, as demonstrated by the increase of T-regulatory (CD4/CD25/FOXP3 positive) and T-exhausted (CD8/PD-1positive) lymphocytes and the M2 polarization (high CD163/CD68 ratio) of macrophages in the neoplastic microenvironment. It is noteworthy that our findings depicted a static picture of a long-lasting dynamic process that might evolve in the development of tumors in other anatomical sites. Here we present the case of a patient affected by rectal squamous cell carcinoma in which we demonstrated the presence of Human Papillomavirus (HPV) by a variety of techniques. Collectively, the virus was detected not only in the tumor but also in some regional lymph nodes and in non-neoplastic mucosa of the upper tract of large bowel. By contrast, it was not identifiable in its common sites of entry, namely oral and ano-genital region. We also found HPV DNA in the plasma-derived exosome. Next, by in vitro studies, we confirmed the capability of HPV DNA-positive exosomes, isolated from the supernatant of a HPV DNA positive cell line (CaSki), to transfer its DNA to human colon cancer and normal cell lines. In the stroma nearby the tumor mass we were able to demonstrate the presence of virus DNA in the stromal compartment, supporting its potential to be transferred from epithelial cells to the stromal ones. Thus, this case report favors the notion that human papillomavirus DNA can be vehiculated by exosomes in the blood of neoplastic patients and that it can be transferred, at least in vitro, to normal and neoplastic cells. Furthermore, we showed the presence of viral DNA and RNA in pluripotent stem cells of non-tumor tissue, suggesting that after viral integration (as demonstrated by p16 and RNA in situ hybridization positivity), stem cells might have been activated into cancer stem cells inducing neoplastic transformation of normal tissue through the inactivation of p53, p21, and Rb. It is conceivable that the virus has elicited its oncogenic effect in this specific site and not elsewhere, despite its wide anatomical distribution in the patient, for a local condition of immune suppression, as demonstrated by the increase of T-regulatory (CD4/CD25/FOXP3 positive) and T-exhausted (CD8/PD-1positive) lymphocytes and the M2 polarization (high CD163/CD68 ratio) of macrophages in the neoplastic microenvironment. It is noteworthy that our findings depicted a static picture of a long-lasting dynamic process that might evolve in the development of tumors in other anatomical sites. Copyright © 2019 Ambrosio, Vernillo, De Carolis, Carducci, Mundo, Ginori, Rocca, Nardone, Lucenti Fei, Carfagno, Lazzi, Cricca and Tosi.
- Published
- 2019
19. Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse
- Author
-
Maria Teresa Del Vecchio, Mariarosaria Boccellino, Leonardo Semeraro, Gaetano Facchini, Bruno Jim Rocca, Tommaso Carfagno, Luigi Pirtoli, Gianluca Vischi, Anna Grimaldi, Michele Caraglia, Massimiliano Berretta, Elodia Claudia Martino, Cirino Botta, Paolo Tini, Pierosandro Tagliaferri, Pierpaolo Correale, Pierfrancesco Tassone, Aurora Barone, Maria Raffaella Ambrosio, Valerio Nardone, Gabriella Misso, Nardone, Valerio, Botta, Cirino, Caraglia, Michele, Martino, Elodia Claudia, Ambrosio, Maria Raffaella, Carfagno, Tommaso, Tini, Paolo, Semeraro, Leonardo, Misso, Gabriella, Grimaldi, Anna, Boccellino, Mariarosaria, Facchini, Gaetano, Berretta, Massimiliano, Vischi, Gianluca, Rocca, Bruno Jim, Barone, Aurora, Tassone, Pierfrancesco, Tagliaferri, Pierosandro, del Vecchio, Maria Teresa, Pirtoli, Luigi, Correale, Pierpaolo, Nardone V., Botta C., Caraglia M., Martino E.C., Ambrosio M.R., Carfagno T., Tini P., Semeraro L., Misso G., Grimaldi A., Boccellino M., Facchini G., Berretta M., Vischi G., Rocca B.J., Barone A., Tassone P., Tagliaferri P., del Vecchio M.T., Pirtoli L., and Correale P.
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_treatment ,Programmed Cell Death 1 Receptor ,Chemokyne Receptor 7 ,Prostate cancer ,0302 clinical medicine ,Recurrence ,PD-1 ,Tumor Microenvironment ,Forkhead Transcription Factors ,hemic and immune systems ,prostate cancer ,Primary tumor ,disease-free survival ,FoxP3 ,overall survival ,prognosis ,radiotherapy ,T regulators lymphocytes ,tumor infiltrating lymphocytes ,030220 oncology & carcinogenesis ,Molecular Medicine ,prognosi ,Research Paper ,Receptors, CCR7 ,medicine.medical_specialty ,chemical and pharmacologic phenomena ,03 medical and health sciences ,Lymphocytes, Tumor-Infiltrating ,Median follow-up ,Internal medicine ,Pharmacology ,medicine ,Humans ,Progression-free survival ,Radical surgery ,Aged ,Salvage Therapy ,business.industry ,Tumor-infiltrating lymphocytes ,Prostatic Neoplasms ,medicine.disease ,Radiation therapy ,T regulators lymphocyte ,030104 developmental biology ,Tumor progression ,tumor infiltrating lymphocyte ,business - Abstract
Tumor immunologic microenvironment is strongly involved in tumor progression and the presence of tumor infiltrating lymphocytes (TIL) with different phenotypes has been demonstrated to be of prognostic relevance in different malignancies. We investigated whether TIL infiltration of tumor tissues could also predict the outcome of prostate cancer patients. To this end, we carried out a retrospective analysis correlating the outcome of locally advanced prostate cancer patients undergone salvage radiotherapy upon relapse after radical surgery with the infiltration by different TIL populations. Twenty-two patients with resectable prostate cancer, with a mean age of 67 (+/−3.93) years, who received salvage radiotherapy with a mean of 69.66 (+/− 3.178) Gy in 8 weeks, between June 1999 and January 2009 and with a median follow up of 123 (+/− 55.82) months, were enrolled in this study. We evaluated, by immunohistochemistry, the intratumoral (t) and peripheral stroma (p) infiltration by CD45, CD3, CD4, CD8, CCR7, FoxP3 or PD-1-positive cells on tumor samples taken at the diagnosis (d) and relapse times (R). We correlated these variables with patients' biochemical progression free survival (bPFS), post-radiotherapy progression free survival (PFS), and overall survival (OS). Substantial changes in the rate of TIL subsets were found between the first and the second biopsy with progressive increase in CD4, CCR7, FoxP3, PD-1+ cells. Our analysis revealed that higher CD8p,R+ and lower PD-1R+ TIL scores correlated to a longer bPFS. Higher CD8p,R+ and CCR7t,R+ TIL scores and lower CD45p,R+ and FoxP3p,R+ TIL scores correlated to a prolonged PFS and OS. These results suggest that the immunological microenvironment of primary tumor is strictly correlated with patient outcome and provide the rationale for immunological treatment of prostate cancer.
- Published
- 2016
20. Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients
- Author
-
Giuseppe Battaglia, Pierfrancesco Tassone, Cristina Ulivieri, Maria Grazia Rossetti, Elodia Claudia Martino, Tommaso Carfagno, Antonella Fioravanti, Francesco Salvatore Carbone, Luigi Pirtoli, Tatiana Cosima Baldari, Giacomo Maria Guidelli, Sara Cheleschi, Claudia Gandolfo, Pierosandro Tagliaferri, Cirino Botta, Maria Grazia Cusi, Pierpaolo Correale, Correale P., Botta C., Martino E.C., Ulivieri C., Battaglia G., Carfagno T., Rossetti M.G., Fioravanti A., Guidelli G.M., Cheleschi S., Gandolfo C., Carbone F., Baldari T.C., Tassone P., Tagliaferri P., Pirtoli L., and Cusi M.G.
- Subjects
0301 basic medicine ,medicine.medical_specialty ,epitope peptides ,Immunology ,GOLFIG chemo-immunotherapy ,thymidylate synthase ,Gastroenterology ,Thymidylate synthase ,CTLs ,03 medical and health sciences ,0302 clinical medicine ,Bolus (medicine) ,Sargramostim ,Internal medicine ,peptide vaccine ,Medicine ,Immunology and Allergy ,Original Research ,biology ,business.industry ,Colon cancer ,Oncology ,Gemcitabine ,Oxaliplatin ,Regimen ,030104 developmental biology ,Fluorouracil ,030220 oncology & carcinogenesis ,Concomitant ,CTL ,biology.protein ,business ,epitope peptide ,medicine.drug - Abstract
Thymidylate synthase (TS) is a tumor-associated enzyme critical for DNA replication and main 5′-fluorouracil (5′-FU) target. TSPP/VAC1 is a multi-arm trial phase-Ib trial program aimed to investigate the toxicity and biomodulatory activity of a poly-epitope-peptide vaccine to TS (TSPP) in cancer patients (pts). Here, we present the results of the TSPP/VAC1/arm C trial aimed to evaluate TSPP in combination with chemo-immunotherapy in pretreated metastatic colo-rectal cancer (mCRC) pts. Twenty-nine pts, 14 males and 15 females, received poly-chemotherapy with gemcitabine [GEM; 1,000mg/sqm, day-1], oxaliplatin [OX; 80mg/sqm, day-2], levofolinate [100mg/sqm, days 1–2], bolus/infusional 5′-FU [400mg/800mg/sqm, days 1–2], sargramostim [50μg, days 3–7/q30], and interleukin-2 [sc. 0.5 MIU twice a day, days 8–14/18–30] [GOLFIG-regimen]. Seventeen pts received sc. TSPP injections at escalating dosage [3 pts, 100µg (DL-1); 3 pts, 200µg (DL-2) and 11pts, 300µg (DL-3)] one week after each chemotherapy cycle (concomitant module), while 10 out 12 pts received TSPP (300µg) after 12 GOLFIG courses [dose level (DL)-0] (sequential module). TSPP MTD was not achieved. Adverse events consisted in swelling/erythema at injection sites (17 cases), G1–2 haematological (16 cases) and gastro-enteric events (12), fever, rhinitis, conjunctivitis, and poly-arthralgia and rise in auto-antibodies [ANA, ENA, c-ANCA, p-ANCA in the DL1–3 pts]. Both treatment-modules showed immunomodulating and antitumor activity (disease-control-rate, DL1–3 and DL0 were 70.6% and 83.3%, respectively) with a better survival recorded in the second group [median OS DL1–3vs. DL0 = 8vs. 16mo, p = 0.049]. The promising long-term survival produced by the sequential treatment module deserves further phase II evaluation.
- Published
- 2016
21. Tumor infiltration by T lymphocytes correlates with the outcome of prostate cancer patients treated with salvage radiotherapy
- Author
-
P. Correale, Tommaso Carfagno, Michele Caraglia, M. Del Vecchio, Luigi Pirtoli, Cirino Botta, Maria Raffaella Ambrosio, Valerio Nardone, Paolo Tini, Pierosandro Tagliaferri, Nardone, V, Botta, C, Ambrosio, Mr, Carfagno, T, Tini, P, Del Vecchio, Mt, Caraglia, M, Tagliaferri, P, Pirtoli, L, and Correale, P
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Hematology ,T lymphocyte ,medicine.disease ,Radiation therapy ,03 medical and health sciences ,Prostate cancer ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Salvage radiotherapy ,medicine ,business ,Infiltration (medical) - Published
- 2016
22. Inflammatory status and lymphocyte of infiltration of primary tumor predict survival of prostate cancer patients undergone prostate radical radiotherapy
- Author
-
L. Semeraro, Maria Raffaella Ambrosio, Valerio Nardone, P. Correale, G. Vischi, Tommaso Carfagno, P. Ferrara, Luigi Pirtoli, Pierpaolo Pastina, Aurora Barone, E.C. Martino, Carfagno, T, Semeraro, L, Nardone, V, Vischi, G, Ferrara, P, Ambrosio, M, Barone, A, Martino, E, Pastina, P, Pirtoli, L, and Correale, P
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Lymphocyte ,Urology ,Radical radiotherapy ,Hematology ,medicine.disease ,Primary tumor ,Radiation therapy ,Prostate cancer ,medicine.anatomical_structure ,Prostate ,Internal medicine ,Medicine ,business ,Infiltration (medical) - Published
- 2015
23. Re: Response to Recommendation of Regional Hyperthermia in the Treatment of Breast Cancer.
- Author
-
Fiorentini G, Sarti D, Gadaleta CD, Ballerini M, Fiorentini C, Carfagno T, Ranieri G, and Guadagni S
- Subjects
- Combined Modality Therapy, Female, Humans, Hyperthermia, Breast Neoplasms therapy, Hyperthermia, Induced
- Published
- 2021
- Full Text
- View/download PDF
24. Putative Role of Circulating Human Papillomavirus DNA in the Development of Primary Squamous Cell Carcinoma of the Middle Rectum: A Case Report.
- Author
-
Ambrosio MR, Vernillo R, De Carolis S, Carducci A, Mundo L, Ginori A, Rocca BJ, Nardone V, Lucenti Fei A, Carfagno T, Lazzi S, Cricca M, and Tosi P
- Abstract
Here we present the case of a patient affected by rectal squamous cell carcinoma in which we demonstrated the presence of Human Papillomavirus (HPV) by a variety of techniques. Collectively, the virus was detected not only in the tumor but also in some regional lymph nodes and in non-neoplastic mucosa of the upper tract of large bowel. By contrast, it was not identifiable in its common sites of entry, namely oral and ano-genital region. We also found HPV DNA in the plasma-derived exosome. Next, by in vitro studies, we confirmed the capability of HPV DNA-positive exosomes, isolated from the supernatant of a HPV DNA positive cell line (CaSki), to transfer its DNA to human colon cancer and normal cell lines. In the stroma nearby the tumor mass we were able to demonstrate the presence of virus DNA in the stromal compartment, supporting its potential to be transferred from epithelial cells to the stromal ones. Thus, this case report favors the notion that human papillomavirus DNA can be vehiculated by exosomes in the blood of neoplastic patients and that it can be transferred, at least in vitro , to normal and neoplastic cells. Furthermore, we showed the presence of viral DNA and RNA in pluripotent stem cells of non-tumor tissue, suggesting that after viral integration (as demonstrated by p16 and RNA in situ hybridization positivity), stem cells might have been activated into cancer stem cells inducing neoplastic transformation of normal tissue through the inactivation of p53, p21, and Rb. It is conceivable that the virus has elicited its oncogenic effect in this specific site and not elsewhere, despite its wide anatomical distribution in the patient, for a local condition of immune suppression, as demonstrated by the increase of T-regulatory (CD4/CD25/FOXP3 positive) and T-exhausted (CD8/PD-1positive) lymphocytes and the M2 polarization (high CD163/CD68 ratio) of macrophages in the neoplastic microenvironment. It is noteworthy that our findings depicted a static picture of a long-lasting dynamic process that might evolve in the development of tumors in other anatomical sites.
- Published
- 2019
- Full Text
- View/download PDF
25. Magnetic-Resonance-Imaging Texture Analysis Predicts Early Progression in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiation.
- Author
-
Nardone V, Reginelli A, Scala F, Carbone SF, Mazzei MA, Sebaste L, Carfagno T, Battaglia G, Pastina P, Correale P, Tini P, Pellino G, Cappabianca S, and Pirtoli L
- Abstract
Background: We hypothesized that texture analysis (TA) from the preoperative MRI can predict early disease progression (ePD), defined as the percentage of patients who relapsed or showed distant metastasis within three months from the radical surgery, in patients with locally advanced rectal cancer (LARC, stage II and III, AJCC) undergoing neoadjuvant chemoradiotherapy (C-RT)., Methods: This retrospective monoinstitutional cohort study included 49 consecutive patients in total with a newly diagnosed rectal cancer. All the patients underwent baseline abdominal MRI and CT scan of the chest and abdomen to exclude distant metastasis before C-RT. Texture parameters were extracted from MRI performed before C-RT (T1, DWI, and ADC sequences) using LifeX Software, a dedicated software for extracting texture parameters from radiological imaging. We divided the cohort in a training set of 34 patients and a validation set of 15 patients, and we tested the data sets for homogeneity, considering the clinical variables. Then we performed univariate and multivariate analysis, and a ROC curve was also generated., Results: Thirteen patients (26.5%) showed an ePD, three of whom with lung metastases and ten with liver relapse. The model was validated based on the prediction accuracy calculated in a previously unseen set of 15 patients. The prediction accuracy of the generated model was 82% (AUC = 0.853) in the training and 80% (AUC = 0.833) in the validation cohort. The only significant features at multivariate analysis was DWI GLCM Correlation (OR: 0.239, p < 0.001)., Conclusion: Our results suggest that TA could be useful to identify patients that may develop early progression.
- Published
- 2019
- Full Text
- View/download PDF
26. Texture analysis as a predictor of radiation-induced xerostomia in head and neck patients undergoing IMRT.
- Author
-
Nardone V, Tini P, Nioche C, Mazzei MA, Carfagno T, Battaglia G, Pastina P, Grassi R, Sebaste L, and Pirtoli L
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Retrospective Studies, Software, Head and Neck Neoplasms radiotherapy, Parotid Gland radiation effects, Radiographic Image Interpretation, Computer-Assisted, Radiotherapy, Intensity-Modulated adverse effects, Tomography, X-Ray Computed, Xerostomia etiology
- Abstract
Purpose: Image texture analysis (TA) is a heterogeneity quantifying approach that cannot be appreciated by the naked eye, and early evidence suggests that TA has great potential in the field of oncology. The aim of this study is to evaluate parotid gland texture analysis (TA) combined with formal dosimetry as a factor for predicting severe late xerostomia in patients undergoing radiation therapy for head and neck cancers., Methods: We performed a retrospective analysis of patients treated at our Radiation Oncology Unit between January 2010 and December 2015, and selected the patients whose normal dose constraints for the parotid gland (mean dose < 26 Gy for the bilateral gland) could not be satisfied due to the presence of positive nodes close to the parotid glands. The parotid gland that showed the higher V30 was contoured on CT simulation and analysed with LifeX Software©. TA parameters included features of grey-level co-occurrence matrix (GLCM), neighbourhood grey-level dependence matrix (NGLDM), grey-level run length matrix (GLRLM), grey-level zone length matrix (GLZLM), sphericity, and indices from the grey-level histogram. We performed a univariate and multivariate analysis between all the texture parameters, the volume of the gland, the normal dose parameters (V30 and Mean Dose), and the development of severe chronic xerostomia., Results: Seventy-eight patients were included and 25 (31%) developed chronic xerostomia. The TA parameters correlated with severe chronic xerostomia included V30 (OR 5.63), Dmean (OR 5.71), Kurtosis (OR 0.78), GLCM Correlation (OR 1.34), and RLNU (OR 2.12). The multivariate logistic regression showed a significant correlation between V30 (0.001), GLCM correlation (p: 0.026), RLNU (p: 0.011), and chronic xerostomia (p < 0.001, R2:0.664)., Conclusions: Xerostomia represents an important cause of morbidity for head and neck cancer survivors after radiation therapy, and in certain cases normal dose constraints cannot be satisfied. Our results seem promising as texture analysis could enhance the normal dose constraints for the prediction of xerostomia.
- Published
- 2018
- Full Text
- View/download PDF
27. Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.
- Author
-
Cencini E, Puccini B, Rigacci L, Fabbri A, Kovalchuk S, Mannelli L, Benelli G, Carfagno T, Simontacchi G, Bocchia M, and Bosi A
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological adverse effects, Chemoradiotherapy, Female, Humans, Lymphoma, Follicular mortality, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Retrospective Studies, Rituximab administration & dosage, Rituximab adverse effects, Survival Analysis, Treatment Outcome, Young Adult, Antineoplastic Agents, Immunological therapeutic use, Lymphoma, Follicular pathology, Lymphoma, Follicular therapy, Radiotherapy methods, Rituximab therapeutic use
- Abstract
Early-stage follicular lymphoma (FL) can be cured with involved-field radiotherapy (IF-RT); however, many patients relapse in non-irradiated areas. A combined association with chemotherapy could increase treatment efficacy, but toxic effects could be unacceptable. In vitro synergistic effect between rituximab (R) and RT has been observed, but clinical data are limited. We retrospectively analyzed 41 early-stage FL patients receiving R and IF-RT as first-line treatment. We administered R 375mg/m
2 weekly for four courses, before or after IF-RT (median dose 24 Gy). Primary outcome was PFS, secondary endpoints were CR rate, OS and safety. All patients achieved CR, after a median follow-up of 46 months only three patients relapsed after 18, 26 and 42 months; estimated 5-year PFS was 90%. We suggest R in association with IF-RT could represent a feasible first-line treatment option for early-stage FL and could increase efficacy without additional toxicity compared to available data about RT alone.- Published
- 2018
- Full Text
- View/download PDF
28. 3D bone texture analysis as a potential predictor of radiation-induced insufficiency fractures.
- Author
-
Nardone V, Tini P, Croci S, Carbone SF, Sebaste L, Carfagno T, Battaglia G, Pastina P, Rubino G, Mazzei MA, and Pirtoli L
- Abstract
Background: The aim of our work is to assess the potential role of texture analysis (TA), applied to computed tomography (CT) simulation scans, in relation to the development of insufficiency fractures (IFs) in patients undergoing radiation therapy (RT) for pelvic malignancies., Methods: We analyzed patients undergoing pelvic RT from Jan-2010 to Dec-2016, 31 of whom had developed IFs of the pelvis. We analyzed CT simulation scans using LifeX Software
© , and in particular we selected three regions of interest (ROI): L5 body, the sacrum and both the femoral heads. The ROI were automatically contoured using the treatment planning software Raystation© . TA parameters included parameters from the gray-level histogram, indices from sphericity and from the matrix of GLCM (gray level co-occurrence matrix). The IFs patients were matched (1:1 ratio) with control patients who had not developed IFs, and were matched for age, sex, type of tumor, menopausal status, RT dose and use of chemotherapy. Univariate and multivariate analyses (logistic regression) were used for statistical analysis., Results: Significant TA parameters on univariate analysis included both parameters from the histogram distribution, as well from the matrix of GLCM. On logistic regression analysis the significant parameters were L5-energy [P=0.033, odds ratio (OR): 1.997, 95% CI: 1.059-3.767] and FH-Skewness (P=0.014, OR: 2.338, 95% CI: 1.191-4.591), with a R2: 0.268. A ROC curve was generated from the binary logistic regression, and the AUC was 0.741 (95% CI: 0.627-0.855, P=0.001, S.E.: 0.058)., Conclusions: In our experience, 3D-bone CT TA can be used to stratify the risk of the patients to develop radiation-induced IFs. A prospective study will be conducted to validate these findings., Competing Interests: Conflicts of Interest: The authors have no conflicts of interest to declare.- Published
- 2018
- Full Text
- View/download PDF
29. Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy.
- Author
-
Detti B, D'Angelillo RM, Ingrosso G, Olmetto E, Francolini G, Triggiani L, Bruni A, Borghesi S, Fondelli S, Carfagno T, Santini R, Santoni R, Trodella LE, and Livi L
- Subjects
- Aged, Aged, 80 and over, Combined Modality Therapy, Humans, Male, Middle Aged, Survival Analysis, Androstenes therapeutic use, Cytochrome P-450 Enzyme Inhibitors therapeutic use, Prostatic Neoplasms, Castration-Resistant drug therapy, Prostatic Neoplasms, Castration-Resistant radiotherapy
- Abstract
Background/aim: This multicenter, retrospective, 'field-practice' study investigated treatment outcomes of ongoing abiraterone therapy with the addition of radiotherapy (RT) - initiated for oligoprogression or with a palliative intent., Patients and Methods: Consecutive patients affected by metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate were considered if they had received RT after the initiation of abiraterone treatment., Results: A total of 32 patients were enrolled in the study. Median duration of abiraterone treatment was 13.0 months (range=3.8-40.9 months). Median duration of abiraterone treatment before RT was 5.9 months (range=0.4-40.0 months), and 7.2 months after RT (range=0.1-29.7 months). Median progression-free survival (PFS) was 12.6 months (95%CI=10.5-14.7) from the initiation of abiraterone treatment. From RT administration, PFS was 9.6 months (95%CI=6.4-12.9). Median overall survival (OS) since abiraterone initiation was 18.9 months (95%CI=4.7-33.0)., Conclusion: RT prolongs abiraterone treatment in mCRPC patients leading to better clinical outcomes with this molecule., (Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
30. Perilesional edema in brain metastasis from non-small cell lung cancer (NSCLC) as predictor of response to radiosurgery (SRS).
- Author
-
Tini P, Nardone V, Pastina P, Battaglia G, Vinciguerra C, Carfagno T, Rubino G, Carbone SF, Sebaste L, Cerase A, Federico A, and Pirtoli L
- Subjects
- Aged, Aged, 80 and over, Brain diagnostic imaging, Brain radiation effects, Brain surgery, Brain Edema diagnostic imaging, Brain Edema therapy, Brain Neoplasms complications, Brain Neoplasms diagnostic imaging, Carcinoma, Non-Small-Cell Lung therapy, Disease Progression, Disease-Free Survival, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Radiosurgery, Retrospective Studies, Severity of Illness Index, Brain Edema etiology, Brain Neoplasms secondary, Brain Neoplasms therapy, Carcinoma, Non-Small-Cell Lung pathology
- Abstract
Radiosurgery (SRS) is widely used in the treatment of brain oligo-metastases from NSCLC. The aim of present study is to evaluate the extent of perilesional edema in brain metastases as predictive factor of treatment response. This single center retrospective study included 42 consecutive patients (January 2011-December 2014) with 1-2 brain metastasis from NSCLC treated with Radiosurgery (SRS). Extent of perilesional edema was measured as maximal extension from the edge of lesion and classified as minor (<10 mm) or major (≥10 mm). We analyzed Modality of Brain Recurrence (MBR), classified as in-field or out-of- field, and Brain Progression Free-Survival (BPFS) after treatment stratified according to extent of perilesional edema. Analyzing modality of brain recurrence and BPFS, after a median follow-up of 6 months, we found that patients with minor edema had a better radiological response to SRS with none in-field recurrences and a lower risk of the onset of new brain lesions (out-of-field recurrence). Instead, patients group with major edema had a worse response rate of lesions treated, further, a higher risk of out-of-field brain relapse. Extent of perilesional edema in brain metastasis from NSCLC could be a predictive factor of response and brain progression after SRS treatment alone.
- Published
- 2017
- Full Text
- View/download PDF
31. Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.
- Author
-
Nardone V, Botta C, Caraglia M, Martino EC, Ambrosio MR, Carfagno T, Tini P, Semeraro L, Misso G, Grimaldi A, Boccellino M, Facchini G, Berretta M, Vischi G, Rocca BJ, Barone A, Tassone P, Tagliaferri P, Del Vecchio MT, Pirtoli L, and Correale P
- Subjects
- Aged, Forkhead Transcription Factors biosynthesis, Humans, Male, Programmed Cell Death 1 Receptor biosynthesis, Prostatic Neoplasms pathology, Receptors, CCR7 biosynthesis, Recurrence, Tumor Microenvironment, Forkhead Transcription Factors immunology, Lymphocytes, Tumor-Infiltrating immunology, Programmed Cell Death 1 Receptor immunology, Prostatic Neoplasms immunology, Prostatic Neoplasms radiotherapy, Receptors, CCR7 immunology, Salvage Therapy methods
- Abstract
Tumor immunologic microenvironment is strongly involved in tumor progression and the presence of tumor infiltrating lymphocytes (TIL) with different phenotypes has been demonstrated to be of prognostic relevance in different malignancies. We investigated whether TIL infiltration of tumor tissues could also predict the outcome of prostate cancer patients. To this end, we carried out a retrospective analysis correlating the outcome of locally advanced prostate cancer patients undergone salvage radiotherapy upon relapse after radical surgery with the infiltration by different TIL populations. Twenty-two patients with resectable prostate cancer, with a mean age of 67 (+/-3.93) years, who received salvage radiotherapy with a mean of 69.66 (+/- 3.178) Gy in 8 weeks, between June 1999 and January 2009 and with a median follow up of 123 (+/- 55.82) months, were enrolled in this study. We evaluated, by immunohistochemistry, the intratumoral (
t ) and peripheral stroma (p ) infiltration by CD45, CD3, CD4, CD8, CCR7, FoxP3 or PD-1-positive cells on tumor samples taken at the diagnosis (d ) and relapse times (R ). We correlated these variables with patients' biochemical progression free survival (bPFS), post-radiotherapy progression free survival (PFS), and overall survival (OS). Substantial changes in the rate of TIL subsets were found between the first and the second biopsy with progressive increase in CD4, CCR7, FoxP3, PD-1+ cells. Our analysis revealed that higher CD8p,R+ and lower PD-1R+ TIL scores correlated to a longer bPFS. Higher CD8p,R+ and CCR7t,R+ TIL scores and lower CD45p,R+ and FoxP3p,R+ TIL scores correlated to a prolonged PFS and OS. These results suggest that the immunological microenvironment of primary tumor is strictly correlated with patient outcome and provide the rationale for immunological treatment of prostate cancer.- Published
- 2016
- Full Text
- View/download PDF
32. Prognostic Value of MR Imaging Texture Analysis in Brain Non-Small Cell Lung Cancer Oligo-Metastases Undergoing Stereotactic Irradiation.
- Author
-
Nardone V, Tini P, Biondi M, Sebaste L, Vanzi E, De Otto G, Rubino G, Carfagno T, Battaglia G, Pastina P, Cerase A, Mazzoni LN, Banci Buonamici F, and Pirtoli L
- Abstract
Unlabelled: BACKGROUND : Stereotactic irradiation is widely used in brain oligo-metastases treatment. The aim of this study is to evaluate the prognostic value of magnetic resonance imaging (MRI) texture analysis (TA) of brain metastases (BM) of non-small cell lung cancer (NSCLC). MATERIALS AND METHODS : This study included thirty-eight consecutive patients undergoing stereotactic irradiation, that is, stereotactic fractionated radiotherapy (SRT) or radiosurgery (SRS), from January 2011 to December 2014 for 1-2 brain BM from NSCLC. Whole-brain radiotherapy (WBRT) was not delivered. The diagnostic MRI DICOM (Digital Imaging and Communications in Medicine) images were collected and analyzed with a homemade ImageJ macro, and typical TA parameters (mean, standard deviation, skewness, kurtosis, entropy, and uniformity) were evaluated for: brain progression-free survival; modality of brain metastatic progression (local progression or/and new metastases); and overall survival, after SRT/SRS., Results: After SRT/SRS 14 patients (36.8%) experienced recurrence in the brain, with a recurrence in the irradiated site (five patients, 13.2%), new metastases (11 patients, 28.9%), local recurrence and new metastases (two patients, 5.25%). Nineteen patients (50%) died of tumor progression or other causes. Entropy and uniformity were significantly associated with local progression, whereas kurtosis was significantly associated with both local progression and new brain metastases. CONCLUSIONS : These results appear promising, since the knowledge of factors correlated with the modality of brain progression after stereotactic irradiation of brain oligo-metastatic foci of NSCLC might help in driving the best treatment in these patients (association of SRT/SRS with WBRT? Increase of SRT/SRS dose?). Our preliminary data needs confirmation in large patient series.
- Published
- 2016
- Full Text
- View/download PDF
33. Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.
- Author
-
Correale P, Botta C, Martino EC, Ulivieri C, Battaglia G, Carfagno T, Rossetti MG, Fioravanti A, Guidelli GM, Cheleschi S, Gandolfo C, Carbone F, Baldari TC, Tassone P, Tagliaferri P, Pirtoli L, and Cusi MG
- Abstract
Thymidylate synthase (TS) is a tumor-associated enzyme critical for DNA replication and main 5'-fluorouracil (5'-FU) target. TSPP/VAC1 is a multi-arm trial phase-Ib trial program aimed to investigate the toxicity and biomodulatory activity of a poly-epitope-peptide vaccine to TS (TSPP) in cancer patients (pts). Here, we present the results of the TSPP/VAC1/arm C trial aimed to evaluate TSPP in combination with chemo-immunotherapy in pretreated metastatic colo-rectal cancer (mCRC) pts. Twenty-nine pts, 14 males and 15 females, received poly-chemotherapy with gemcitabine [GEM; 1,000 mg/sqm, day-1], oxaliplatin [OX; 80 mg/sqm, day-2], levofolinate [100 mg/sqm, days 1-2], bolus/infusional 5'-FU [400 mg/800 mg/sqm, days 1-2], sargramostim [50 μg, days 3-7/q30], and interleukin-2 [sc. 0.5 MIU twice a day, days 8-14/18-30] [GOLFIG-regimen]. Seventeen pts received sc. TSPP injections at escalating dosage [3 pts, 100 µg (DL-1); 3 pts, 200 µg (DL-2) and 11pts, 300 µg (DL-3)] one week after each chemotherapy cycle (concomitant module), while 10 out 12 pts received TSPP (300 µg) after 12 GOLFIG courses [dose level (DL)-0] (sequential module). TSPP MTD was not achieved. Adverse events consisted in swelling/erythema at injection sites (17 cases), G1-2 haematological (16 cases) and gastro-enteric events (12), fever, rhinitis, conjunctivitis, and poly-arthralgia and rise in auto-antibodies [ANA, ENA, c-ANCA, p-ANCA in the DL1-3 pts]. Both treatment-modules showed immunomodulating and antitumor activity (disease-control-rate, DL1-3 and DL0 were 70.6% and 83.3%, respectively) with a better survival recorded in the second group [median OS DL1-3 vs. DL0 = 8 vs. 16 mo, p = 0.049]. The promising long-term survival produced by the sequential treatment module deserves further phase II evaluation.
- Published
- 2015
- Full Text
- View/download PDF
34. Diffusion-weighted magnetic resonance diagnosis of local recurrences of prostate cancer after radical prostatectomy: preliminary evaluation on twenty-seven cases.
- Author
-
Carbone SF, Pirtoli L, Ricci V, Carfagno T, Tini P, La Penna A, Cacchiarelli E, and Volterrani L
- Subjects
- Aged, Humans, Male, Prostate pathology, Prostate surgery, ROC Curve, Reference Standards, Diffusion Magnetic Resonance Imaging, Neoplasm Recurrence, Local diagnosis, Neoplasm Recurrence, Local surgery, Prostatectomy, Prostatic Neoplasms diagnosis, Prostatic Neoplasms surgery
- Abstract
Objectives: To assess the diagnostic performance of diffusion-weighted MR imaging (DWI) in patients affected by prostatic fossa (PF) relapse after radical prostatectomy (RP) for prostatic carcinoma (PC)., Methods: Twenty-seven patients showing a nodular lesion in the PF at T2-weighted MR imaging after RP, with diagnosis of PC relapse established by biopsy or PSA determinations, were investigated by DWI. Two readers evaluated the DWI results in consensus and the apparent diffusion coefficient (ADC) of the nodules, separately; a mean value was obtained (ADCm)., Results: Relapses did not significantly differ in size in respect of postsurgical benign nodules. The DWI qualitative evaluation showed sensitivity, specificity, accuracy, ppv, and npv values, respectively, of 83.3%, 88.9%, 85.2%, 93.7%, and 72.7% (100%, 87.5%, 95.6%, 93.7%, and 100%, for nodules >6 mm). The intraclass correlation coefficient (ICC) for ADC evaluation between the two readers was 0.852 (95% CI 0.661-0.935; P = 0.0001). The ADCm values for relapses and benign nodules were, respectively, 0.98 ± 0.21 × 10(-3) mm(2)/sec and 1.24 ± 0.32 × 10(-3) mm(2)/sec (P = 0.006). Sensitivity, specificity, accuracy, ppv and npv of ADCm were, respectively, 77.8%, 88.9%, 81.8%, 93.3%, and 66.7% (93.3%, 87.5%, 85.4%, 93.3%, and 87.5% for nodules >6 mm)., Conclusions: Diffusion-weighted MR imaging is a promising tool in the management of a hyperintense nodule detected by T2-weighted sequences. This might have a relevant importance in contouring radiotherapy treatment volumes.
- Published
- 2014
- Full Text
- View/download PDF
35. Diffusion-weighted MR volumetry for assessing the response of rectal cancer to combined radiation therapy with chemotherapy.
- Author
-
Carbone SF, Pirtoli L, Ricci V, Carfagno T, Tini P, Lazzi S, and Volterrani L
- Subjects
- Female, Humans, Male, Antineoplastic Agents therapeutic use, Diffusion Magnetic Resonance Imaging methods, Imaging, Three-Dimensional methods, Radiotherapy, Conformal methods, Rectal Neoplasms diagnosis, Rectal Neoplasms therapy
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.